Roche today announced the opening of the new Pharmaceutical Research and Development Center (pRED) at its global headquarters in Basel. Equipped with cutting-edge technologies and housing around 1,800 state-of-the-art laboratory and office workstations, the new center brings together researchers from different disciplines to advance scientific discoveries for patients.

Severin Schwan, Chairman of the Board of Directors of the Roche Group: “Roche has invested CHF 1.2 billion in the new pRED Center. This underlines our ongoing commitment to supporting Switzerland as a leading innovative location for life sciences – the country where Roche was founded over 125 years ago.”

Thomas Schinecker, CEO of the Roche Group: “The new pRED Center will play an important role in collaborating with our innovation centers around the world and increasing the efficiency of our research and development to achieve the greatest benefit for patients.”

Hans Clevers, Head of Pharmaceutical Research and Early Development (pRED): “By investing in the new pRED Center, we are further advancing scientific research to turn innovations into new medicines and thus better meet the needs of our patients. The new center will enable greater interaction and knowledge exchange between different disciplines, for example between chemists, biologists and data scientists.”

The new pRED Center consists of two laboratory towers (114 m, 72 m) with state-of-the-art laboratory technologies and digital solutions, as well as an office building and a congress center (26 m, 18 m). In total, there are 33 combined laboratories and office floors with 150 laboratories and workspaces for around 1800 researchers. The state-of-the-art buildings were deliberately designed to promote collaboration and an end-to-end mindset in order to bring the most innovative medicines to patients faster.

Since 2009, Roche has invested CHF 4.6 billion in expanding the Basel/Kaiseraugst site, with the inauguration of the pRED Center being the largest single investment. In addition, we are currently investing a further CHF 1.2 billion at the Basel site. In total, investments in the development of the Basel/Kaiseraugst site from 2009 to 2030 amount to CHF 5.8 billion.

Further information and photos can be found at www.roche.ch .

About Roche
Founded in Basel, Switzerland in 1896 as one of the first industrial manufacturers of branded pharmaceuticals, Roche has grown to become the world's largest biotechnology company and the global leader in in vitro diagnostics. The company strives for scientific excellence to discover and develop medicines and diagnostics that improve and save the lives of people around the world. We are a pioneer in the field of personalized medicine and want to further advance the way healthcare is delivered to achieve even greater benefits. To ensure that everyone receives the best possible treatment, we work with many partners and combine our strengths in diagnostics and pharmaceuticals with insights from data from clinical practice.

Sustainability has been an integral part of our business for over 125 years. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that improve people's lives. Roche is committed to achieving net zero emissions by 2045 as part of the Science Based Targets Initiative and the Sustainable Markets Initiative.

Genentech in the USA is wholly owned by the Roche Group. Roche is the majority shareholder of Chugai Pharmaceutical, Japan.

For further information, please visit www.roche.com .

All brand names mentioned are protected by law

Roche Group Media Relations
Telephone: +41 61 688 8888 / e-mail: media.relations@roche.com

 

Source: globenewswire.com

Report Abuse